Onchee Yu, MS, is a biostatistician who has contributed her extensive experience in statistical applications to electronic health records (EHR) data to studies related to women’s health, pharmacoepidemiology, and vaccine safety and effectiveness. Ms. Yu has been a key member of Kaiser Permanente Washington Health Research Institute’s (KPWHRI) immunization research program for 20 years. Her work focuses on applying statistical methods to evaluate vaccine effectiveness, side effects, and safety. In collaboration with KPWHRI biostatisticians Jennifer Nelson, PhD, and Andrea Cook, PhD, Ms. Yu developed and improved statistical methods for monitoring the safety of postmarketing vaccines in the Vaccine Safety Datalink project.
Much of Ms. Yu's recent research is in pharmacoepidemiology, which is studying how drugs are used in a population and their impact on public health. She is an expert in statistical analysis in a complex, clinically important area—determining if taking medicine for one condition (for example, cardiovascular medications) affects risk of other illnesses (for example, cancer outcomes).
Ms. Yu also contributes to women’s health. Using extensive EHR data and in collaboration with University of Washington clinician and KPWHRI affiliate researcher Susan D. Reed, MD, MPH, Ms. Yu has estimated incidences and prevalences, validated diagnosis codes, and developed automated case-finding algorithms for women’s health conditions including uterine fibroids, adenomyosis and endometriosis.
Ms. Yu obtained her MS in biostatistics from the University of Washington in 1999. She is a member of the American Statistical Association and the International Society for Pharmacoepidemiology. Her statistical methodological expertise includes classification and regression tree analysis, and survival analysis.
Survival analysis; classification and regression tree analysis
Biostatistics; medication use and cancer outcomes
Biostatistics; vaccine safety and efficacy; postmarketing vaccine safety study design and analysis
Biostatistics; incidence and prevalence estimations; validation of diagnosis codes; automated case-finding algorithms
Biostatistics; medication use and cancer outcomes; postmarketing drug and vaccine safety study design and analysis; safety signal detection methods
Aiello Bowles EJ, Boudreau DM, Chubak J, Yu O, Fujii M, Chestnut J, Buist DS. Patient reported discontinuation of endocrine therapy and related side effects among women with early stage breast cancer. J Oncol Prac. Nov 1 2012:e149-57. PubMed
Chubak J, Yu O, Pocobelli G, Lamerato L, Webster J, Prout MN, Ulcickas Yood M, Barlow WE, Buist DS. Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. J Natl Cancer Inst. 2012 Jun 20;104(12):931-40. Epub 2012 Apr 30. PubMed
Aiello Bowles EJ, Buist DS, Chubak J, Yu O, Johnson J, Chestnut J, Boudreau DM. Endocrine therapy initiation from 2001 through 2008 varies by age of breast cancer diagnosis and tumor size. J Oncol Pract. 2012;8(2):113-20. PubMed
Scholes D, Satterwhite CL, Yu O, Fine D, Weinstock H, Berman S. Long-term trends in Chlamydia trachomatis infections and related outcomes in a US managed care population. Sex Transm Dis. 2012;39(2):81-8. PubMed
Nelson JC, Cook AJ, Yu O, Dominguez C, Zhao S, Greene SK, Fireman BH, Jacobsen SJ, Weintraub ES, Jackson LA. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data. Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:62-71. doi: 10.1002/pds.2324. PubMed
A trial led by KPWHRI researchers found that adding nurse care managers helped more people get needed treatment.
Researchers gain better understanding of polycystic ovary syndrome's impact in U.S.
Researchers find a relationship between prescribed central nervous system-active medications and increased risk of falling among older people with dementia.